Search Videos and More
News
Race, Ethnicity, and Poverty Linked to Worse Outcomes in Children Treated for High-Risk Neuroblastoma
Children with high-risk neuroblastoma had worse outcomes if they were from certain racial/ethnic groups or were on public rather than private insurance, despite being treated in clinical trials with standardized protocols, according to a study led by investigators from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
News
Scientists Identify Potential Target in Ewing Sarcoma Cells
Investigators led by Dana-Farber Cancer Institute’s Kimberly Stegmaier, MD, have discovered that knocking out a protein regulator in Ewing sarcoma cells causes the tumor cells to die from an overdose of a cancer-promoting protein.
News
Venetoclax Added to Chemotherapy Improves Outcomes in Type of Leukemia
Adding the BCL-2 inhibitor drug venetoclax to a combination chemotherapy regimen significantly improved outcomes in Richter’s syndrome, a rare but deadly complication that develops in some patients with chronic lymphocytic leukemia (CLL), according to a study led by Dana-Farber investigators.
News
Venetoclax Shown to Benefit Patients with Waldenström Macroglobulinemia, Including Some Who Relapsed After Previous Therapy
A drug that strips cancer cells of their quest for immortality represents an effective new option for patients with Waldenström macroglobulinemia, including those not helped by the only class of drugs currently approved to treat the disease, a clinical trial by Dana-Farber Cancer Institute investigators demonstrates.
News
Mantle Cell Lymphoma Clinical Trial
Targeted combination therapy for mantle cell lymphoma with minimal residual disease assessment.
Video
Phase 3 Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) or Everolimus (EVE) Versus Sunitinib (SUN) Monotherapy as a First-Line Treatment for Patients (pts) with Advanced Renal Cell Carcinoma (RCC) (CLEAR Study
Kidney Cancer Research: Toni Choueiri, MD details results from the phase 3 CLEAR study that showed significant benefits from the combination of lenvatinib, an oral kinase inhibitor, and pembrolizumab, a checkpoint inhibitor in advanced kidney cancer.